Career Enhancement Program
职业提升计划
基本信息
- 批准号:10709236
- 负责人:
- 金额:$ 8.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-19 至 2028-07-31
- 项目状态:未结题
- 来源:
- 关键词:American Association of Cancer ResearchAmerican Society of Clinical OncologyAreaAwardBasic ScienceBudgetsCancer BiologyCancer Research ProjectClinicalClinical ResearchCollaborationsDedicationsDevelopmentDevelopment PlansDiagnosisDiseaseEarly DiagnosisEarly treatmentEducationEnsureFacultyFosteringFoundationsFundingGoalsGrantHealthcareInstitutionInternationalInterventionInvestigationLaboratoriesLeadershipMalignant neoplasm of ovaryMentorsMentorshipMinorityMorbidity - disease rateNational Center for Advancing Translational SciencesOvarianPaperPatientsPeer ReviewPostdoctoral FellowPreventionPublishingResearchResearch PersonnelResourcesScientistTrainingTranslatingTranslational ResearchUnited States National Institutes of HealthUniversity of Texas M D Anderson Cancer CenterWomanWorkWritinganticancer researchbench to bedsidecancer diagnosiscareercareer developmentclinical caredesignexperienceimprovedinnovationmeetingsmembermortalitynext generationnovelprogramsrecruitsupportive environmentsymposiumtranslational approach
项目摘要
Career Enhancement Program SUMMARY/ABSTRACT
The central goal of the Career Enhancement Program (CEP) is to use the resources at MD Anderson to train
exceptional young investigators who will reduce the morbidity and mortality from ovarian cancer by making
advances in the early detection, prevention, and treatment of this disease. To achieve this goal, the SPORE
CEP will provide two awards, each of $50,000 annually for up to two years, funded from the SPORE and
matching funds from MD Anderson. The intent of each CEP award is to prepare the selected scientists to become
international leaders in academic research relevant to ovarian cancer. We will achieve this through focused
recruitment of a diverse cadre of promising young investigators. We will work in partnership with awardees to
generate individualized development plan and provide them with outstanding clinical and a laboratory mentors
and a mentoring committee, formal course work, coaching in grant and paper writing, leadership training,
attendance at national meetings, networking with ovarian cancer scholars and completing and publishing a
translational ovarian cancer research program. Over the past two decades, the Ovarian Cancer SPORE CEP
has developed the careers of 27 young investigators. In the first year of the original grant, three postdoctoral
trainees received CEP awards, and of the 24 faculty members supported since 2000, all but two have remained
in academic research and 13 are engaged predominantly in ovarian cancer research. Seventeen have achieved
federal peer-reviewed funding and five additional awardees have received competitive foundation grants. Three
awardees from our 2017-2021 funded cycle have received two Ovarian Cancer Research Alliance (OCRA)
Awards, one CPRIT award, one R01, one R21, and one U01. Since the inception of the program in 1999, our
CEP awardees have published over 1,100 peer-reviewed papers regarding ovarian cancer.
职业提升计划摘要/摘要
职业提升计划(CEP)的中心目标是利用MD Anderson的资源进行培训
杰出的年轻研究人员,他们将通过制定
该病的早期发现、预防和治疗方面的进展。为了实现这一目标,孢子
CEP将提供两个奖项,每个奖项每年50,000美元,最长两年,由孢子和
MD Anderson提供的配套资金。每个CEP奖项的目的都是为了让入选的科学家做好准备,成为
与卵巢癌相关的学术研究的国际领先者。我们将通过集中精力实现这一目标
招募有前途的年轻调查人员的多样化干部队伍。我们将与获奖者合作
制定个性化的发展计划,为他们提供优秀的临床和实验室导师
以及一个指导委员会,正式的课程工作,助学金和论文写作的指导,领导力培训,
出席全国会议,与卵巢癌学者建立联系,完成并出版了一份
转化性卵巢癌研究计划。在过去的二十年里,卵巢癌孢子CEP
发展了27名年轻调查人员的职业生涯。在最初拨款的第一年,三名博士后
受训人员获得了CEP奖,自2000年以来得到支持的24名教职员工中,除两人外,所有人都留了下来
在学术研究方面,13人主要从事卵巢癌研究。有17个人已经实现了
联邦同行评审的资金和另外五名获奖者获得了竞争性基金会的赠款。三
2017-2021年资助周期的获奖者获得了两个卵巢癌研究联盟(OCRA)
奖项,一个CPRIT奖,一个R01,一个R21和一个U01。自1999年该计划开始以来,我们的
CEP奖获得者发表了1100多篇关于卵巢癌的同行评议论文。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT C BAST其他文献
ROBERT C BAST的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT C BAST', 18)}}的其他基金
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer
SIK2 抑制剂 GRN-300 增强卵巢癌中 PARP 抑制剂的敏感性和细胞毒性 T 细胞功能
- 批准号:
10709229 - 财政年份:2023
- 资助金额:
$ 8.52万 - 项目类别:
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer
德克萨斯大学 MD 安德森癌症中心 SPORE 在卵巢癌中的应用
- 批准号:
10709227 - 财政年份:2023
- 资助金额:
$ 8.52万 - 项目类别:
DIRAS3 disrupts K-RAS clustering and signaling, enhancing autophagy and response to autophagy inhibition
DIRAS3 破坏 K-RAS 聚类和信号传导,增强自噬和对自噬抑制的反应
- 批准号:
10707965 - 财政年份:2022
- 资助金额:
$ 8.52万 - 项目类别:
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms
开发用于早期检测算法的新型卵巢癌生物标志物
- 批准号:
10410452 - 财政年份:2020
- 资助金额:
$ 8.52万 - 项目类别:
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms
开发用于早期检测算法的新型卵巢癌生物标志物
- 批准号:
10226017 - 财政年份:2020
- 资助金额:
$ 8.52万 - 项目类别:
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms
开发用于早期检测算法的新型卵巢癌生物标志物
- 批准号:
10670063 - 财政年份:2020
- 资助金额:
$ 8.52万 - 项目类别:
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms
开发用于早期检测算法的新型卵巢癌生物标志物
- 批准号:
9916297 - 财政年份:2020
- 资助金额:
$ 8.52万 - 项目类别:
Project 4: SIK2 PROVIDES A NOVEL TARGET FOR OVARIAN CANCER THERAPY IN COMBINATION WITH PACLITAXEL AND INHIBITORS OF PARP
项目 4:SIK2 结合紫杉醇和 PARP 抑制剂为卵巢癌治疗提供新靶点
- 批准号:
10005298 - 财政年份:2017
- 资助金额:
$ 8.52万 - 项目类别:
相似海外基金
EVALUATION OF IOWA CANCER REGISTRY DATA LINKAGE WITH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) CANCERLINQ. POP 9/10/19 - 9/9/20.
评估爱荷华州癌症登记处与美国临床肿瘤学会 (ASCO) CANCERLINQ 的数据链接。
- 批准号:
10026959 - 财政年份:2019
- 资助金额:
$ 8.52万 - 项目类别: